The current state of patient access to new drugs in South Korea under the positive list system: evaluation of the changes since the new review pathways. (2nd January 2021)

• Record Type: Journal Article
• Authors: Kim, Sungju; Cho, Hyunyoung; Kim, Jinhong; Lee, Kyungmin; Lee, Jong Hyuk
• Is Part Of: Expert review of pharmacoeconomics & outcomes research. Volume 21:Number 1(2021)
• Page Start: 119
• Page End: 126
• Publication Date: 2021-01-02
• Subjects: Patient access -- listing rate -- lead time -- risk-sharing agreements -- price negotiation waiver -- pharmacoeconomic evaluation exemption; Pharmacology -- Economic aspects -- Periodicals; 338.47615105
• DOI: 10.1080/14737167.2020.1758559
• Languages: English
• ISSNs: 1473-7167

Abstract

ABSTRACT: Objective : This study aims to provide an up-to-date analysis of the current state of patient access to new drugs in South Korea, focusing on the effect of new review pathways for reimbursement. Methods : We analyzed patients' access to new drugs, listing rate and lead time until listing from marketing authorization. New pathways were defined as 'price negotiation waiver, ' 'risk-sharing agreements, ' and 'pharmacoeconomic evaluation exemption.' Results : The listing rate for drugs increased after the introduction of the new pathways (93.7% vs. 77.9%, p < 0.001). Before the new pathways, the median lead time for listing was 21.0 months (95% CI: 16.9–25.0), while afterward it was shortened to 10.9 months (95% CI: 10.2–11.7) (p < 0.001). Conclusion : Although it has strengthened national health insurance coverage by positively impacting the rate and lead time, the lead time for the oncology and orphan drugs is substantially longer as compared to other drugs. Expanding the eligibility criteria to include non-life-threatening but rare or intractable diseases, and resolving the system's operational issues are still necessary.